2100 WHARTON STREET, PITTSBURGH, PA
Other Events
Announces Second Quarter 2025 Financial and Operating Results
Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
Investor Presentation
Shareholder votes
Expansion of an HSV-1-Based Gene Therapy Platform to Treat Hailey-Hailey and Darier Diseases
Earnings Release
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus Filed Pursuant to Rule 424(b)(2)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
S-1MEF